210 related articles for article (PubMed ID: 31761386)
1. Recent advance in the development of novel, selective and potent FGFR inhibitors.
Liu FT; Li NG; Zhang YM; Xie WC; Yang SP; Lu T; Shi ZH
Eur J Med Chem; 2020 Jan; 186():111884. PubMed ID: 31761386
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models.
Chew NJ; Lim Kam Sian TCC; Nguyen EV; Shin SY; Yang J; Hui MN; Deng N; McLean CA; Welm AL; Lim E; Gregory P; Nottle T; Lang T; Vereker M; Richardson G; Kerr G; Micati D; Jardé T; Abud HE; Lee RS; Swarbrick A; Daly RJ
Breast Cancer Res; 2021 Aug; 23(1):82. PubMed ID: 34344433
[TBL] [Abstract][Full Text] [Related]
3. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
Roskoski R
Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide and Its Analogs Differentially Target Fibroblast Growth Factor Receptors: Thalidomide Suppresses FGFR Gene Expression while Pomalidomide Dampens FGFR2 Activity.
Sundaresan L; Kumar P; Manivannan J; Balaguru UM; Kasiviswanathan D; Veeriah V; Anishetty S; Chatterjee S
Chem Res Toxicol; 2019 Apr; 32(4):589-602. PubMed ID: 30834740
[TBL] [Abstract][Full Text] [Related]
5. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
Katoh M
Int J Mol Med; 2016 Jul; 38(1):3-15. PubMed ID: 27245147
[TBL] [Abstract][Full Text] [Related]
6. Structure-Based Discovery of a Series of 5H-Pyrrolo[2,3-b]pyrazine FGFR Kinase Inhibitors.
Jiang A; Liu Q; Wang R; Wei P; Dai Y; Wang X; Xu Y; Ma Y; Ai J; Shen J; Ding J; Xiong B
Molecules; 2018 Mar; 23(3):. PubMed ID: 29562726
[TBL] [Abstract][Full Text] [Related]
7. Recent advances of dual FGFR inhibitors as a novel therapy for cancer.
Liang Q; Wang J; Zhao L; Hou J; Hu Y; Shi J
Eur J Med Chem; 2021 Mar; 214():113205. PubMed ID: 33556787
[TBL] [Abstract][Full Text] [Related]
8. Differential distribution of fibroblast growth factor receptors (FGFRs) on foveal cones: FGFR-4 is an early marker of cone photoreceptors.
Cornish EE; Natoli RC; Hendrickson A; Provis JM
Mol Vis; 2004 Jan; 10():1-14. PubMed ID: 14737068
[TBL] [Abstract][Full Text] [Related]
9. A structure-guided approach to creating covalent FGFR inhibitors.
Zhou W; Hur W; McDermott U; Dutt A; Xian W; Ficarro SB; Zhang J; Sharma SV; Brugge J; Meyerson M; Settleman J; Gray NS
Chem Biol; 2010 Mar; 17(3):285-95. PubMed ID: 20338520
[TBL] [Abstract][Full Text] [Related]
10. E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.
Watanabe Miyano S; Yamamoto Y; Kodama K; Miyajima Y; Mikamoto M; Nakagawa T; Kuramochi H; Funasaka S; Nagao S; Sugi NH; Okamoto K; Minoshima Y; Nakatani Y; Karoji Y; Ohashi I; Yamane Y; Okada T; Matsushima T; Matsui J; Iwata M; Uenaka T; Tsuruoka A
Mol Cancer Ther; 2016 Nov; 15(11):2630-2639. PubMed ID: 27535969
[TBL] [Abstract][Full Text] [Related]
11. Anticancer molecules targeting fibroblast growth factor receptors.
Liang G; Liu Z; Wu J; Cai Y; Li X
Trends Pharmacol Sci; 2012 Oct; 33(10):531-41. PubMed ID: 22884522
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of pyrazolylaminoquinazoline derivatives as highly potent pan-fibroblast growth factor receptor inhibitors.
Fan J; Dai Y; Shao J; Peng X; Wang C; Cao S; Zhao B; Ai J; Geng M; Duan W
Bioorg Med Chem Lett; 2016 Jun; 26(11):2594-9. PubMed ID: 27117427
[TBL] [Abstract][Full Text] [Related]
13. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors.
Dai S; Zhou Z; Chen Z; Xu G; Chen Y
Cells; 2019 Jun; 8(6):. PubMed ID: 31216761
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel Ponatinib analogues for reducing KDR activity as potent FGFRs inhibitors.
Liu Y; Peng X; Guan X; Lu D; Xi Y; Jin S; Chen H; Zeng L; Ai J; Geng M; Hu Y
Eur J Med Chem; 2017 Jan; 126():122-132. PubMed ID: 27750146
[TBL] [Abstract][Full Text] [Related]
16. An overview of the binding models of FGFR tyrosine kinases in complex with small molecule inhibitors.
Cheng W; Wang M; Tian X; Zhang X
Eur J Med Chem; 2017 Jan; 126():476-490. PubMed ID: 27914362
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of novel FGFR inhibitors bearing an indazole scaffold.
Liu J; Peng X; Dai Y; Zhang W; Ren S; Ai J; Geng M; Li Y
Org Biomol Chem; 2015 Jul; 13(28):7643-54. PubMed ID: 26080733
[TBL] [Abstract][Full Text] [Related]
18. The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.
Nakanishi Y; Akiyama N; Tsukaguchi T; Fujii T; Sakata K; Sase H; Isobe T; Morikami K; Shindoh H; Mio T; Ebiike H; Taka N; Aoki Y; Ishii N
Mol Cancer Ther; 2014 Nov; 13(11):2547-58. PubMed ID: 25169980
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor receptor inhibitors: patent review (2015-2019).
Marseglia G; Lodola A; Mor M; Castelli R
Expert Opin Ther Pat; 2019 Dec; 29(12):965-977. PubMed ID: 31679402
[No Abstract] [Full Text] [Related]
20. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
